196 related articles for article (PubMed ID: 29856615)
1. Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.
Grimster NP; Anderson E; Alimzhanov M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Gero T; Harsch A; Huszar D; Kawatkar A; Kettle JG; Lyne P; Read JA; Rivard Costa C; Ruston L; Schroeder P; Shi J; Su Q; Throner S; Toader D; Vasbinder M; Woessner R; Wang H; Wu A; Ye M; Zheng W; Zinda M
J Med Chem; 2018 Jun; 61(12):5235-5244. PubMed ID: 29856615
[TBL] [Abstract][Full Text] [Related]
2. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
[TBL] [Abstract][Full Text] [Related]
3. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
4. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
5. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
[TBL] [Abstract][Full Text] [Related]
8. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
10. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
11. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
Rashid S; Bibi N; Parveen Z; Shafique S
J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication.
Reiterer G; Yen A
Cancer Res; 2006 Sep; 66(18):9083-9. PubMed ID: 16982750
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
[TBL] [Abstract][Full Text] [Related]
15. Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.
Lu K; Wu W; Zhang C; Liu Z; Xiao B; Yuan Z; Li A; Chen D; Zhai X; Jiang Y
Bioorg Med Chem Lett; 2020 Jul; 30(14):127225. PubMed ID: 32527540
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
Yamagishi H; Shirakami S; Nakajima Y; Tanaka A; Takahashi F; Hamaguchi H; Hatanaka K; Moritomo A; Inami M; Higashi Y; Inoue T
Bioorg Med Chem; 2015 Aug; 23(15):4846-4859. PubMed ID: 26059596
[TBL] [Abstract][Full Text] [Related]
17. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.
Labadie S; Barrett K; Blair WS; Chang C; Deshmukh G; Eigenbrot C; Gibbons P; Johnson A; Kenny JR; Kohli PB; Liimatta M; Lupardus PJ; Shia S; Steffek M; Ubhayakar S; van Abbema A; Zak M
Bioorg Med Chem Lett; 2013 Nov; 23(21):5923-30. PubMed ID: 24042009
[TBL] [Abstract][Full Text] [Related]
18. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
19. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
[TBL] [Abstract][Full Text] [Related]
20. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.
Liang J; van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair W; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liu Y; Lyssikatos J; Mantik P; Menghrajani K; Murray J; Peng I; Sambrone A; Shia S; Shin Y; Smith J; Sohn S; Tsui V; Ultsch M; Wu LC; Xiao Y; Yang W; Young J; Zhang B; Zhu BY; Magnuson S
J Med Chem; 2013 Jun; 56(11):4521-36. PubMed ID: 23668484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
